Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.69 |
| ▸ | CTSL | P07711 | 5/20 | 0.69 |
| ▸ | CTSB | P07858 | 4/20 | 0.69 |
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184084 | 0.82 | CTSL (1.00) | CTSSCTSLCTSBCTSK | |
| SCHEMBL6183581 | 0.81 | CTSS (0.98) | CTSSCTSLCTSBCTSK | |
| SCHEMBL5520069 | 0.80 | CTSS (0.62) | CTSSCTSLCTSBCTSKLMNA | |
| SCHEMBL1839379 | 0.79 | CTSS (0.67) | CTSSCTSLCTSBCTSKPOLB | |
| SCHEMBL8981148 | 0.79 | CTSS (0.67) | CTSSCTSLCTSBCTSKPOLB | |
| SCHEMBL8981228 | 0.79 | CTSS (0.67) | CTSSCTSLCTSBCTSKPOLB | |
| SCHEMBL8981271 | 0.79 | CTSS (0.67) | CTSSCTSLCTSBCTSKPOLB | |
| SCHEMBL8981223 | 0.79 | CTSS (0.67) | CTSSCTSLCTSBCTSKPOLB | |
| SCHEMBL14772158 | 0.79 | LMNA (0.65) | CTSSCTSLCTSBCTSKLMNA | |
| SCHEMBL1151498 | 0.78 | CTSS (0.65) | CTSSCTSLCTSBCTSKPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12324812-B2 | Glucopyranosyl derivatives and their uses | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-06-10 | — | — | US | disclosed |
| CN-112209908-B | Glucopyranosyl derivatives and uses thereof | 东莞市东阳光新药研发有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230086354-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-03-23 | — | — | US | disclosed |
| CN-110066302-B | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-03-04 | — | — | US | disclosed |
| CN-112209908-A | Glucopyranosyl derivative and use thereof | 东莞市东阳光新药研发有限公司 | 2021-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | CTSS 3594/4885CTSL 4037/4885CTSB 3805/4885 |
| US-20230086354-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES | SLC5A1, SLC5A2, UGGT1 | CTSS 3058/4885CTSL 3636/4885CTSB 3082/4885 |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | CTSS 3594/4885CTSL 4037/4885CTSB 3805/4885 |
| US-12324812-B2 | Glucopyranosyl derivatives and their uses | SLC5A1, SLC5A2, UGGT1 | CTSS 3170/4885CTSL 3747/4885CTSB 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.